China’s Top Insulin Maker Gan & Lee Pharma Responds To Bribery Issue
This article was originally published in PharmAsia News
China’s top insulin manufacturer Gan & Lee Pharmaceuticals said it is conducting an internal investigation of its sales representatives allegedly involved in bribery in Hubei province.
You may also be interested in...
Stephen Hahn’s low visibility period as the newly installed FDA commissioner comes to an abrupt end. Trump offers generous praise amid COVID-19 response – but how quickly might that change to blame?
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.